PRKAA2 and pulmonary arterial hypertension: The present study demonstrates that knockdown of AMPKα2 stimulated PASMCs proliferation, suggesting that enhancing AMPKα2 activity might be a novel therapeutic strategy in the prevention and treatment of PAH.